B-1004. Comparison of Telavancin and Vancomycin for Prevention of In Vivo Staphylococcal Device-Associated Infections
Session: Poster Session: Antistaphylococcal Therapy Testing in Animal Models
Sunday, October 26, 2008: 12:00 AM
Room: Hall C
Background: Telavancin (TLV) is an investigational lipoglycopeptide that operates through a multifunctional mechanism and displays bactericidal activity against Gram-positive pathogens including staphylococci. This study compared vancomycin (VAN) and TLV for the prevention of staphylococcal colonization and infection of surgically implanted devices.Methods: Female rabbits were randomly administered a single IV dose of 5% dextrose (D5W), VAN 20 mg/kg, or TLV (15 mg/kg, 30 mg/kg or 45 mg/kg) before the subcutaneous implantation of catheter segments (6 segments/rabbit; 9 rabbits/54 devices per treatment group). The catheters were inoculated with S. aureus P1 MSSA strain (105 CFU) and the wounds sutured. One week post surgery the animals were sacrificed and bacterial cultures were obtained from the devices, surrounding tissues, and blood. Results: All groups of systemic antibiotic prophylaxis were associated with significantly (p<0.0001) lower rates of device colonization and device-related infection than the control group (Table). TLV (15 mg/kg), at a clinically subtherapeutic dose, was non-inferior to VAN in preventing device colonization and device-related infection. Clinically therapeutic doses of TLV (30 or 45 mg/kg), were superior (p<0.0001) to VAN in preventing device colonization and device-related infection. All blood cultures were sterile. Conclusions: The results from this animal study suggest that further study of the preoperative administration of TLV as an effective approach to prevent staphylococcal colonization and infection of surgical implants in humans is warranted.
Device Colonization and Infection Rates
Colonization col./total(%)Infection inf./total(%)
D5W (control)48/48 (100%)48/48 (100%)
VAN 20 mg/kg28/54 (52%)28/54 (52%)
TLV 15 mg/kg21/54 (39%)19/54 (35%)
TLV 30 mg/kg6/54 (11%)5/54 (9%)
TLV 45 mg/kg6/54 (11%)6/54 (11%)
Marlowe Schneidkraut1, Mohammad Mansouri, BS2, Rabih Darouiche, MD2 and  R. O. Darouiche,
Astellas Pharma US, Inc. Role(s): Research Relationship, Received: Research Support., (1)Astellas Pharma US Inc., (2)Baylor College of Medicine, Houston, TX